Tag: Pacific Biosciences
Illumina to Acquire Pacific Biosciences for Approximately $1.2 Billion, Broadening Access to Long-Read Sequencing and Accelerating Scientific Discovery
SAN DIEGO & MENLO PARK, Calif.–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) and Pacific Biosciences (NASDAQ:PACB) today announced they have signed an agreement for Illumina to acquire Pacific Biosciences at a price of $8.00 per Pacific Biosciences share in an all-cash transaction. This price represents a premium of 71% to Pacific Biosciences’ 30 trading day volume weighted... Read more
Pacific Biosciences Announces a New Paradigm in DNA Sequencing – Highly Accurate Single-Molecule Long Reads
Significant Enhancements to Sequel System Enable >99% Accuracy for Single-Molecule Reads up to 15 kb; Throughput Increases by 2- to 4-FoldMENLO PARK, Calif., Oct. 10, 2018 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq:PACB), the leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced major enhancements to its Sequel® System, including... Read more
Pacific Biosciences Releases Highest-Quality, Most Contiguous Individual Human Genome Assembly to Date
MENLO PARK, Calif., Oct. 08, 2018 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq:PACB), the leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced it has produced the most contiguous diploid human genome assembly of a single individual to date, representing the nearly complete DNA sequence from all 46 chromosomes inherited... Read more
Large-Scale Global Genome Projects Choose PacBio Sequencing to Help Decode Life
MENLO PARK, Calif., Sept. 13, 2018 (GLOBE NEWSWIRE) — When creating a genomic ark of creatures great and small, scientists across the globe are turning to the comprehensive coverage and quality of long-read sequencing technology from Pacific Biosciences (Nasdaq:PACB), the leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes.Today, the Vertebrate Genomes Project (VGP),... Read more
Pacific Biosciences of California, Inc. Announces Pricing of Public Offering of Common Stock
MENLO PARK, Calif., Sept. 12, 2018 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (NASDAQ: PACB) (the “Company”) today announced that it has priced its previously announced underwritten public offering of 14,117,647 shares of its common stock at a price to the public of $4.25 per share. The offering is expected to close on or... Read more
Pacific Biosciences of California, Inc. Announces Proposed Public Offering of Common Stock
MENLO PARK, Calif., Sept. 10, 2018 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Pacific Biosciences also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the... Read more
Pacific Biosciences Appoints Christian Henry to Board of Directors
MENLO PARK, Calif., July 31, 2018 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq:PACB), the leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced that it has appointed industry veteran Christian Henry to its Board of Directors. Mr. Henry has over 20 years of leadership experience, including over 10 years in... Read more
Pacific Biosciences Selected for NSF Project to Rapidly Sequence Maize Pangenome
MENLO PARK, Calif., July 10, 2018 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq:PACB), the leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced that a multi-institutional consortium of maize researchers is using the Sequel® System to create a 26-line pangenome reference collection. Led by faculty investigator R. Kelly Dawe, Distinguished... Read more